in , ,

Meet Jean-Jacques Muyembe-Tamfum, The Congolese Scientist Who Discovered The Cure For Ebola

On August 12, the World Health Organization (WHO) announced a positive development in the clinical trials of drugs being tested for the treatment of Ebola in the Democratic Republic of Congo (DR of Congo).

WHO asserted that the Ebola drugs showed “advances that will bring patients a better chance of survival,” and further affirmed that “two out of the four drugs being tested are more effective in treating Ebola.”

Who is the man behind the Ebola cure? Esteemed professor Jean-Jacques Muyembe-Tamfum, director-general of the Institut National de Recherche Biomédicale (INRB) DR of Congo, who invested a substantial part of his adult life treating the virus.

While the international media has often focused heavily on the deadly, contagious nature of Ebola in DR of Congo, less has been said about the Congolese scientist who discovered its cure.

This team lead by Dr Jean-Jacques Muyembe-Tamfum initially started with four treatments but only two have shown remarkable promise at treating Ebola.

During the clinical trials, these experimental drugs — an antibody cocktail called REGN-EB3 developed by Regeneron and a monoclonal antibody called mAb114 — improved “survival rates from the disease more than two other treatments being tested.”

They increased the survival rates for infected people from 89 to 94 per cent by attacking the Ebola virus with a combination of monoclonal antibodies that neutralise its deadly effect on human cells.

From now on we will no longer say that Ebola is not curable. This advance will in the future help save thousands of lives that would have had a fatal outcome in the past,” Muyembe, director-general of the Democratic Republic of the Congo’s Institut National de Recherche Biomedicale, announced.


According to Dr Anthony Fauci, director of the US National Institute of Allergy and Infectious Diseases (NIAID), which co-sponsored the trial, the results are “very good news” for the fight against Ebola.

NIAID added: “They are the first drugs that, in a scientifically sound study, have clearly shown a significant diminution in mortality.”

Dr Muyembe started fighting Ebola after the deadly disease made its first appearance in the DRC (formerly known as Zaire) in 1976. He was 34 at the time.

Since then, he has been helping his country in the fight against all outbreaks including the ongoing massive epidemic that started in August 2018.

Explaining how much work has gone into finding a cure, Dr Muyembe told BBC: “I spent four decades of my life thinking about how to treat patients with the Ebola virus. So this is the achievement of my life.”

His hard work finally paid off when two Ebola patients were declared ‘cured’ after using his experimental drugs and released from a treatment centre in Goma, DR Congo.

Asked about how he felt about this, he said: “I’m a little sentimental. I had this idea a long time ago, and I’ve waited patiently for it. I’m very happy, and I can’t believe it.”

Dr Muyembe shared the good news on Tuesday, August 13, 2019, at a press conference in Goma.

He said, “Ebola kills quickly and Ebola heals quickly. That’s the message. These cases were detected very quickly. The husband was infected, he was at home for 10 days and his wife and son were infected. As soon as the response teams detected these cases, they brought them here to the treatment centre. We gave them treatment that is effective and here in a short time both are cured.”

The Congolese doctor added, “We are waiting until the end of the 21-day surveillance period. We are at day 13, so there are still 8 days to go before we can say that Goma has won against Ebola.”

Dr Muyembe’s cure will now be offered to all infected patients at no cost for “compassionate use.”


Written by PH

Leave a Reply

Your email address will not be published. Required fields are marked *


AfDB Approves Loans Of €209 Million For Expansion Of Highway That Links Kenya’s Major Economic Hubs

Kenyan Bank, Sidian Receives $3 Million From OikoCredit To Extend Lending To SMEs